{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"112"}]}],"title":"Neutropenia with a Nadir <500 cells/mm^3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"77"}]}],"title":"Neutropenia with a Nadir <100 cells/mm^3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"title":"Thrombocytopenia with a Nadir <50,000 platelets/mm^3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Thrombocytopenia with a Nadir <25,000 platelets/mm^3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"Anemia: hemoglobin <8 g/dL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0).","groups":[{"description":"Combination chemo and biological therapy\n\nRituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5\n\nFilgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle\n\nEtoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles","id":"OG000","title":"Arm 1-Combination Chemo and Biological Therapy"}],"paramType":"NUMBER","populationDescription":"One participant declined to participate before treatment started.","reportingStatus":"POSTED","timeFrame":"Up to 112 cycles (each cycle is 21 days + 7 days window)","title":"Number of Cycles of Hematologic Toxicity","type":"SECONDARY","unitOfMeasure":"cycles"}